RE:RE:RE:Valuation/ Ray BlancoFarmerBetsy wrote: Value after phase 1, most if not all big pharma names pass phase 1 safety profile testing in Alzheimers trials. Latest trials Prothena and Acumen who started two years ago with their first testing patient announced good safety profile results this summer with a low rate of Aria-e. Didn't see their market value increase 2 billion or any other Pharma. Promis acknowledges they might have low incidence of Aria-e, Acumen to start talking to the regulators this fall about phase 2. Bottom line is phase 2 & 3 is where the rubber hits the road and since 2003, 98% of Alzheimers trials have failed. Folks that have pushed the narrative in the past that Promis will know in a few months if it's going to work good luck with that.
The nonsense continues about July 17th, 14 million trading day with a 8.55 million share float.
We do know in June reported Directors and Executive owned approx- 9.69% of total stock add past president (Nov) Eugene Goldstein's 3.08% plus Title 19( Michael Gordon) and Crocker Jeremy Sclar each at 9.99 % plus JaK11 LLX at 3.37%, you are already in at 35% ownership. Who did the selling and buying on July 17th? It wasn't insiders, we know after the PP Title 19 and Crocker still own between 9-10% ?
Nasday still showing a Promis float of approx- 8.55 millions shares, market cap of 16.9 million, one year target of $ 19.76.
Yahoo has the correct market cap of aprox- 36.6 million @ $1.97 today.
FarmerBetsy, your point is what, in all of this? G1945V